Compare CWT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWT | AGIO |
|---|---|---|
| Founded | 1926 | 2007 |
| Country | United States | United States |
| Employees | 1105 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | 1997 | 2013 |
| Metric | CWT | AGIO |
|---|---|---|
| Price | $50.09 | $34.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $55.00 | $38.88 |
| AVG Volume (30 Days) | 478.3K | ★ 1.1M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $963,695,000.00 | $43,011,000.00 |
| Revenue This Year | $10.18 | $76.75 |
| Revenue Next Year | $5.81 | $170.73 |
| P/E Ratio | $49.76 | ★ N/A |
| Revenue Growth | ★ 6.41 | N/A |
| 52 Week Low | $41.29 | $22.24 |
| 52 Week High | $53.82 | $46.00 |
| Indicator | CWT | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 51.70 |
| Support Level | $48.67 | $26.71 |
| Resistance Level | $50.94 | $36.04 |
| Average True Range (ATR) | 0.79 | 1.29 |
| MACD | -0.04 | 0.20 |
| Stochastic Oscillator | 50.00 | 62.53 |
California Water Service Group is a U.S. water and utilities holding company based in California. The company provides water utility and other related services in California, Washington, New Mexico, Hawaii and Texas through its wholly-owned subsidiaries. The bulk of the company's business consists of the production, purchase, storage, treatment, testing, distribution, and sale of water for domestic, industrial, public, and irrigation uses, and the provision of water for domestic and municipal fire protection services.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.